157 related articles for article (PubMed ID: 11745268)
1. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin.
Fabel K; Dietrich J; Hau P; Wismeth C; Winner B; Przywara S; Steinbrecher A; Ullrich W; Bogdahn U
Cancer; 2001 Oct; 92(7):1936-42. PubMed ID: 11745268
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma.
Hau P; Fabel K; Baumgart U; Rümmele P; Grauer O; Bock A; Dietmaier C; Dietmaier W; Dietrich J; Dudel C; Hübner F; Jauch T; Drechsel E; Kleiter I; Wismeth C; Zellner A; Brawanski A; Steinbrecher A; Marienhagen J; Bogdahn U
Cancer; 2004 Mar; 100(6):1199-207. PubMed ID: 15022287
[TBL] [Abstract][Full Text] [Related]
3. Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series.
Glas M; Koch H; Hirschmann B; Jauch T; Steinbrecher A; Herrlinger U; Bogdahn U; Hau P
Oncology; 2007; 72(5-6):302-7. PubMed ID: 18198491
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Cloughesy TF; Filka E; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
Am J Clin Oncol; 2002 Apr; 25(2):204-8. PubMed ID: 11943904
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.
Tang P; Roldan G; Brasher PM; Fulton D; Roa W; Murtha A; Cairncross JG; Forsyth PA
J Neurooncol; 2006 Jul; 78(3):311-6. PubMed ID: 16710748
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract][Full Text] [Related]
7. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery.
Rostomily RC; Spence AM; Duong D; McCormick K; Bland M; Berger MS
Neurosurgery; 1994 Sep; 35(3):378-88; discussion 388. PubMed ID: 7800129
[TBL] [Abstract][Full Text] [Related]
8. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
10. Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study.
Trippoli S; Pelagotti F; Messori A; Vacca F; Vaiani M; Maltoni S
Drugs R D; 2003; 4(5):285-91. PubMed ID: 12952497
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma.
Chastagner P; Devictor B; Geoerger B; Aerts I; Leblond P; Frappaz D; Gentet JC; Bracard S; André N
Cancer Chemother Pharmacol; 2015 Aug; 76(2):425-32. PubMed ID: 26115930
[TBL] [Abstract][Full Text] [Related]
12. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas.
Grossman SA; Phuphanich S; Lesser G; Rozental J; Grochow LB; Fisher J; Piantadosi S;
J Clin Oncol; 2001 Jul; 19(13):3260-6. PubMed ID: 11432894
[TBL] [Abstract][Full Text] [Related]
13. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.
Harris L; Batist G; Belt R; Rovira D; Navari R; Azarnia N; Welles L; Winer E;
Cancer; 2002 Jan; 94(1):25-36. PubMed ID: 11815957
[TBL] [Abstract][Full Text] [Related]
14. Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.
Wagner S; Peters O; Fels C; Janssen G; Liebeskind AK; Sauerbrey A; Suttorp M; Hau P; Wolff JE
J Neurooncol; 2008 Jan; 86(2):175-81. PubMed ID: 17641821
[TBL] [Abstract][Full Text] [Related]
15. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.
Pérez-Segura P; Manneh R; Ceballos I; García A; Benavides M; Fuster J; Vaz MA; Cano JM; Berros JP; Covela M; Moreno V; Quintanar T; García Bueno JM; Fernández I; Sepúlveda J
Clin Transl Oncol; 2016 Aug; 18(8):805-12. PubMed ID: 26542177
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Gil MJ; de Las Peñas R; Reynés G; Balañá C; Peréz-Segura P; García-Velasco A; Mesia C; Gallego O; Fernández-Chacón C; Martínez-García M; Herrero A; Andrés R; Benavides M; Quintanar T; Pérez-Martin X
Anticancer Drugs; 2012 Jul; 23(6):659-65. PubMed ID: 22634799
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of GRN1005 in recurrent malignant glioma.
Drappatz J; Brenner A; Wong ET; Eichler A; Schiff D; Groves MD; Mikkelsen T; Rosenfeld S; Sarantopoulos J; Meyers CA; Fielding RM; Elian K; Wang X; Lawrence B; Shing M; Kelsey S; Castaigne JP; Wen PY
Clin Cancer Res; 2013 Mar; 19(6):1567-76. PubMed ID: 23349317
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
Muggia FM; Hainsworth JD; Jeffers S; Miller P; Groshen S; Tan M; Roman L; Uziely B; Muderspach L; Garcia A; Burnett A; Greco FA; Morrow CP; Paradiso LJ; Liang LJ
J Clin Oncol; 1997 Mar; 15(3):987-93. PubMed ID: 9060537
[TBL] [Abstract][Full Text] [Related]
20. Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma.
Fink W; Zimpfer-Rechner C; Thoelke A; Figl R; Kaatz M; Ugurel S; Schadendorf D
Onkologie; 2004 Dec; 27(6):540-4. PubMed ID: 15591712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]